Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock
📌 Key Takeaways
- {"type":"skipped","reason":"older_than_6_hours"}
📚 Related People & Topics
Raymond James Financial
American multinational independent investment bank and financial services company
Raymond James Financial, Inc. is an American multinational independent investment bank and financial services company providing financial services to individuals, corporations, and municipalities through its subsidiary companies that engage primarily in investment and financial planning, in addition...
Entity Intersection Graph
Connections for Raymond James Financial:
🌐
Valuation
1 shared
🏢
American Tower
1 shared
👤
Bristow Helicopters
1 shared
🌐
Financial market
1 shared
🌐
Financial statement analysis
1 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices soar as Middle East conflict spurs safe haven demand Oil prices surge after U.S.-Israel strikes on Iran; crude around $80/bbl likely Dollar surges on Middle East conflict; euro, sterling retreat Futures drop, oil spikes amid widening Mideast conflict - what’s moving markets FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock By Investing.com Analyst Ratings Published 03/02/2026, 07:27 AM Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock 0 SPRY -0.64% Investing.com - Raymond James reiterated a Strong Buy rating and $34.00 price target on ARS Pharmaceuticals Inc (NASDAQ:SPRY) . The stock currently trades at $9.28, well below the analyst high target of $39, with InvestingPro data suggesting the company appears undervalued based on its Fair Value analysis. The FDA published a redacted version of the Complete Response Letter issued on Feb. 3 to Aquestive, a competitor of ARS Pharmaceuticals in the needle-free epinephrine space. The CRL does not refer to the wide range of concerns included in ARS Pharmaceuticals’ Citizen Petition, including diastolic blood pressure spike, dynamic oral environment, and repeat-dosing. The CRL focuses on issues that could potentially be resolved with human factors and pharmacokinetics studies. The document does not specify how large the studies proposed by the FDA need to be, though multiple parallel arms, including placebo arms, are recommended. The CRL indicates that the 150-day response to ARS Pharmaceuticals’ Citizen’s Petition will not be issued given the rejection of the Anaphylm submission. Aquestive is guiding toward a 3Q26 timeframe for NDA resubmission. Raymond James assumes that post NDA resubmission, ARS Pharmaceuticals will resubmit its Citizen Petition to restart the 150-day FDA response clock. The firm views the CRL as a positive development for ARS Pharmaceuticals, primaril...
Read full article at source